Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.12)
# 4,317
Out of 4,396 analysts
25
Total ratings
23.8%
Success rate
-32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNTI Senti Biosciences Holdings | Maintained: Buy | n/a | $0.9057 | - | 2 | Dec 15, 2025 | |
| PYXS Pyxis Oncology | Maintained: Buy | $7 | $1.70 | +311.76% | 12 | Aug 15, 2025 | |
| JANX Janux Therapeutics | Maintained: Buy | $87 | $13.66 | +536.90% | 10 | Aug 12, 2025 | |
| MRK Merck & Co. | Rated: Buy | $112 | $119.60 | n/a | 1 | Oct 28, 2022 |
Senti Biosciences Holdings
Dec 15, 2025
Maintained: Buy
Price Target: n/a
Current: $0.9057
Upside: -
Pyxis Oncology
Aug 15, 2025
Maintained: Buy
Price Target: $7
Current: $1.70
Upside: +311.76%
Janux Therapeutics
Aug 12, 2025
Maintained: Buy
Price Target: $87
Current: $13.66
Upside: +536.90%
Merck & Co.
Oct 28, 2022
Rated: Buy
Price Target: $112
Current: $119.60
Upside: n/a